{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:36:36Z","timestamp":1794490596599,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euros.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:37:58Z","timestamp":1758710278000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries"],"prefix":"10.1016","volume":"81","author":[{"given":"Shilpa","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Panattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Flottemesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtuza","family":"Bharmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.08.009_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2025.08.009_b0010","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.euros.2025.08.009_b0015","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2025.08.009_b0020","unstructured":"International Agency for Research on Cancer. Global Cancer Observatory: cancer today. https:\/\/gco.iarc.fr\/."},{"key":"10.1016\/j.euros.2025.08.009_b0025","unstructured":"American Cancer Society. Key statistics for bladder cancer. https:\/\/www.cancer.org\/cancer\/bladder-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.euros.2025.08.009_b0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.08.009_b0040","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer;V1.2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.euros.2025.08.009_b0045","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.08.009_b0050","unstructured":"Keytruda (pembrolizumab) Prescribing information. Merck & Co., Rahway, NJ;2025."},{"key":"10.1016\/j.euros.2025.08.009_b0055","unstructured":"Roche. Roche provides update on Tecentriq US indication for previously untreated metastatic bladder cancer. News release, November 29, 2022. https:\/\/assets.roche.com\/f\/176343\/x\/7f0df2b225\/roche-tecentriq-us-bladder-withdrawal_media-statement_181122-1.pdf."},{"key":"10.1016\/j.euros.2025.08.009_b0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/fon-2023-0298","article-title":"Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis","volume":"20","author":"Kearney","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0065","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.7150\/jca.23162","article-title":"A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany","volume":"9","author":"Niegisch","year":"2018","journal-title":"J Cancer"},{"issue":"6_suppl","key":"10.1016\/j.euros.2025.08.009_b0070","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2022.40.6_suppl.456","article-title":"Disease management and frontline treatment of locally advanced or metastatic urothelial (la\/mUC) carcinoma: the U.S. physician PARADIGM study","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-170149","article-title":"Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States","volume":"4","author":"Galsky","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2025.08.009_b0080","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euros.2025.08.009_b0085","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2023.41.6_suppl.464","article-title":"Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany","volume":"41","author":"Niegisch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0090","article-title":"Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience","volume":"27","author":"Swami","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euros.2025.08.009_b0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/JCO.2019.37.7_suppl.451","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"37","author":"Gupta","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.euros.2025.08.009_b0100","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.euros.2025.08.009_b0105","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0110","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.clgc.2023.09.010","article-title":"Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries","volume":"22","author":"Milloy","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.08.009_b0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.clgc.2021.04.008","article-title":"Clinical outcomes of platinum-ineligible patients with advanced urothelial carcinoma treated with first-line PD1\/L1 inhibitors","volume":"19","author":"Pond","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.08.009_b0120","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.08.009_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","article-title":"Urothelial carcinoma management in elderly or unfit patients","volume":"14","author":"Bellmunt","year":"2016","journal-title":"EJC Suppl"},{"key":"10.1016\/j.euros.2025.08.009_b0130","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"suppl 7","key":"10.1016\/j.euros.2025.08.009_b0135","doi-asserted-by":"crossref","first-page":"S1345","DOI":"10.1016\/j.annonc.2022.07.1843","article-title":"1765P Undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la\/mUC): a systematic literature review","volume":"33","author":"Wilke","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325003015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325003015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:11:57Z","timestamp":1772917917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325003015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"alternative-id":["S2666168325003015"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.08.009","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}